Sign up
Pharma Capital

Pharmaxis seeing a great deal of interest from potential LOXL2 program partners

Gary Phillips, chief executive of Pharmaxis Ltd (ASX:PXS) tells Proactive one of the key events for the company this year will be the mid‐year read out from the phase 1 studies that are underway on the two lead candidates from their anti fibrotic LOXL2 program.

''I've spent the last 12-18 months talking to potential partners'', Phillips says.

''We're looking for a company active in either NASH or IPF which is looking for an anti-fibrotic to add to their pipeline''.

''We've got about 10 companies which are seriously interested in the program we've been running … many of them are already under confidentiality agreements and some of them testing our compound in their laboratories so I can see a great deal of interest in this particular program''.


View full PXS profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.